Navigation Links
European Medicines Agency (EMEA) Approves Cell Therapeutics, Inc.'s September Meeting Request to Discuss OPAXIO(TM) Marketing Authorization Application
Date:7/6/2009

SEATTLE, July 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it had requested and the EMEA has agreed to an oral explanation in support of the OPAXIO Marketing Authorization Application (MAA) in September, 2009 extending the review for the Committee for Medicinal Products for Human Use (CHMP) opinion on approval until Q4-2009. In April, 2008 the EMEA accepted for review the MAA for OPAXIO for first-line treatment of patients with advanced non-small cell lung cancer who are performance status 2, based on a non-inferior survival and improved side effect profile. The previously scheduled June, 2009 meeting with the EMEA on OPAXIO did not occur due to conflicts in regulatory schedule as CTI focused on completing the pixantrone New Drug Application (NDA) submission in June, 2009.

"We are pleased that the EMEA has agreed to an in person oral explanation in September allowing the Company and its lung cancer experts adequate time to prepare a thorough review for the Co-rapporteurs in support of our MAA for OPAXIO in non-small cell lung cancer," said James A. Bianco, M.D., CEO of Cell Therapeutics. "The fourth quarter is shaping up to be a pivotal period for the Company."

About OPAXIO(TM)

OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which was formerly known as XYOTAX(TM), is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that OPAXIO is preferentially distributed to tumors du
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
3. Medical Services International Inc. Completes Testing for European Union (EU) Application
4. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
5. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
6. Launch of second European Cancer Research Funding survey
7. European directive will halt use of MRI scans; cancer diagnosis and treatment will suffer
8. Pharsight to Host European Software Conference
9. OmniGuide Begins European Commercialization
10. Paving the way for future pan-European clinical trials
11. US, European cancer educators gather in Alabama for meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 23, 2014 BambooFlooringChina.com is a ... has proudly released its new collection of bamboo mats ... up to 29% off. , According to the ... tree-like grass, making it a highly renewable resource. Their bamboo ... a mixing color which comes from natural bamboo with caramel ...
(Date:11/22/2014)... York, NY (PRWEB) November 22, 2014 ... Therapeutics Goods Administration (TGA) approved it for use ... was approved and listed within the Therapeutic Goods ... http://www.comlaw.gov.au/Details/F2014L01277 , Kyowa Hakko’s Setria® Glutathione will ... a biotech specialist that sources and imports fine ...
(Date:11/22/2014)... 2014 Discount-Dress.com is an important ... firm is to increase the company’s online market share by ... selection of bridesmaid dresses and announced a bridesmaid dress promotion ... until Dec. 30, 2014. All the dresses from this company ... , In fact, Discount-Dress.com is very good at manufacturing wedding ...
(Date:11/22/2014)... TX (PRWEB) November 22, 2014 ... (ICS) as the complaint that the individual has ... for voiding. The report “Nocturia – Pipeline Review, ... development for Nocturia, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ...
(Date:11/22/2014)... York (PRWEB) November 22, 2014 A ... morcellators ( http://www.morcellatorlawsuit2015.com ) in minimally-invasive hysterectomies and ... signatures since the end of October, Bernstein Liebhard LLP ... the petition as of November 21st, 2014. That represents ... 86,042 supporters had signed on to the campaign.* , ...
Breaking Medicine News(10 mins):Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4
... than Alzheimer,s patients, healthy controls , , MONDAY, Oct. 13 ... than healthy people or Alzheimer,s patients to have vitamin ... of Medicine in Atlanta. , They compared vitamin D ... 99 healthy people matched for age and other factors. ...
... greater effect on women, study found , , MONDAY, Oct. 13 ... your brain shrinks, a new study has found. , ... you,re going to hurt your brain," said Rajesh Miranda, an ... A&M Health Science Center College of Medicine. "This is something ...
... AMERIGROUP Foundation,today announced a contribution in support of ... enhance the organization,s vocational,training program., SCHI is ... underprivileged children with special needs from,throughout New Jersey. ... suffering of the,most vulnerable members of the community. ...
... a Healthy Spine, PLANO, Texas, Oct. 13 ... Back Institute shares "Nine for Your Spine." The,release of ... October 16, 2008., National Spine Health Day was ... the most effective means of reducing the,prevalence and severity ...
... System, Supports Global Pharma Client in Closing ... CHESTER, Pa., Oct. 13 Modevity, LLC announced,today ... Imperium technology to become the primary platform for ... for their new product video content. Imperium is ...
... ANNAPOLIS, Md., Oct. 13 The National Coalition ... concerns over,the National CT Colonography Study published September ... evidence must be closely evaluated, and,patients need to ... risks. The National Coalition reminds patients that Colonoscopy,remains ...
Cached Medicine News:Health News:Parkinson's Patients More Prone to Vitamin D Deficiency 2Health News:Excess Drinking Shrinks the Brain 2Health News:AMERIGROUP Foundation Supports the School for Children with Hidden Intelligence 2Health News:Texas Back Institute Announces 'Nine for Your Spine' for National Spine Health Day - October 16 2Health News:Texas Back Institute Announces 'Nine for Your Spine' for National Spine Health Day - October 16 3Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3
(Date:11/21/2014)... MONTREAL , 21. November 2014 ... hat heute bekannt gegeben, dass ... – EMA) die Kennzeichnung als Orphan-Medizinprodukt ... Produktkandidat des Unternehmens zur Behandlung von ... eine seltene, stark beeinträchtigende genetische Krankheit, ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... , Chief Executive Officer, will be presenting at the 26 ... York Palace Hotel in New York . ... at 2:00 PM ET. In addition, Mr. Krakauer and ... for separate one-on-one meetings during the day. ...
(Date:11/21/2014)... -- Depomed, Inc. (NASDAQ: DEPO ) today announced that ... Annual Healthcare Conference in New York City . ... for 8:00 am EST (5:00 am PST) on Tuesday December 2, ... accessed via the Investor Relations page of the Depomed website at ... for 30 days on the company,s website. About ...
Breaking Medicine Technology:Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2
... April 11, 2012  Blue Mountain Hospital has used an electronic ... announced plans to swap out its original technology with an ... "We were lucky to start out as a ... are using simply is not meeting all of our needs," ...
... BAY, Wis., April 11, 2012   IOD Incorporated™, ... health systems, and physician practices, today announced its response ... a proposed rule to delay ICD-10 from October 1, ... http://photos.prnewswire.com/prnh/20111207/CG18689LOGO ) According to HHS regulations ...
Cached Medicine Technology:Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 2Blue Mountain Hospital Selects Enterprise System from Prognosis HIS 3IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 2IOD Incorporated Advises Healthcare Providers to Stay the Course in Preparation for ICD-10 3
... advancement in supralaryngeal airway management., ,The CobraPLA ... the hypopharynx where it abuts the structure of ... head design of the distal end of the ... epiglottis out of the way, facilitating ventilation through ...
Robertazzi Amber Latex Free Nasal Airways are manufactured from natural amber latex. Soft, flexible maximizing comfort....
Robertazzi Latex Free Nasal Airways are manufactured from soft neoprene and have smooth beveled tip for gentle insertion....
Extra soft for patient comfort., ,The Argyle® Nasopharyngeal Airway provides an open airway to make suctioning and bronchoscopy easier, safer, and less traumatic....
Medicine Products: